company background image
HLA

HealthiaASX:HLA Stock Report

Market Cap

AU$240.6m

7D

6.7%

1Y

91.0%

Updated

18 Oct, 2021

Data

Company Financials +
HLA fundamental analysis
Snowflake Score
Valuation0/6
Future Growth4/6
Past Performance4/6
Financial Health2/6
Dividends3/6

HLA Overview

Healthia Limited provides health services in Australia.

Price History & Performance

Summary of all time highs, changes and price drops for Healthia
Historical stock prices
Current Share PriceAU$1.90
52 Week HighAU$0.99
52 Week LowAU$2.22
Beta1.74
1 Month Change-13.64%
3 Month Change-2.56%
1 Year Change90.96%
3 Year Change63.09%
5 Year Changen/a
Change since IPO59.00%

Recent News & Updates

Sep 17
Earnings Tell The Story For Healthia Limited (ASX:HLA) As Its Stock Soars 30%

Earnings Tell The Story For Healthia Limited (ASX:HLA) As Its Stock Soars 30%

Healthia Limited ( ASX:HLA ) shareholders would be excited to see that the share price has had a great month, posting a...

Sep 17
Healthia Limited (ASX:HLA) Stocks Shoot Up 30% But Its P/E Still Looks Reasonable

Healthia Limited (ASX:HLA) Stocks Shoot Up 30% But Its P/E Still Looks Reasonable

Healthia Limited ( ASX:HLA ) shareholders would be excited to see that the share price has had a great month, posting a...

Sep 01
Healthia (ASX:HLA) Is Increasing Its Dividend To AU$0.025

Healthia (ASX:HLA) Is Increasing Its Dividend To AU$0.025

Healthia Limited's ( ASX:HLA ) dividend will be increasing to AU$0.025 on 27th of October. This makes the dividend...

Shareholder Returns

HLAAU HealthcareAU Market
7D6.7%-0.2%1.7%
1Y91.0%11.0%20.3%

Return vs Industry: HLA exceeded the Australian Healthcare industry which returned 11.5% over the past year.

Return vs Market: HLA exceeded the Australian Market which returned 20.2% over the past year.

Price Volatility

Is HLA's price volatile compared to industry and market?
HLA volatility
HLA Beta1.74
Industry Beta0.60
Market Beta1

Stable Share Price: HLA is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: HLA's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2018n/aWes Cootehttps://www.healthia.com.au

Healthia Limited provides health services in Australia. The company operates 94 podiatry clinics under the My FootDr brand; 52 physiotherapy clinics; and 14 hand therapy clinics, as well as manufactures and sells 3D printed orthotic devices for podiatry clinics. It also offers podiatry and foot and nail care products, hand and upper limb therapies, orthopaedic, optometry, pilates, retail footwear, custom orthotic manufacturing services, and medical products to podiatrists, hospitals, medical centres, nursing homes, and allied health professionals.

Healthia Fundamentals Summary

How do Healthia's earnings and revenue compare to its market cap?
HLA fundamental statistics
Market CapAU$240.59m
Earnings (TTM)AU$5.16m
Revenue (TTM)AU$136.95m

46.7x

P/E Ratio

1.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
HLA income statement (TTM)
RevenueAU$136.95m
Cost of RevenueAU$96.75m
Gross ProfitAU$40.20m
ExpensesAU$35.04m
EarningsAU$5.16m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.041
Gross Margin29.35%
Net Profit Margin3.77%
Debt/Equity Ratio54.3%

How did HLA perform over the long term?

See historical performance and comparison

Dividends

2.6%

Current Dividend Yield

69%

Payout Ratio

Valuation

Is Healthia undervalued compared to its fair value and its price relative to the market?

46.66x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: HLA (A$1.9) is trading above our estimate of fair value (A$1.65)

Significantly Below Fair Value: HLA is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: HLA is poor value based on its PE Ratio (46.7x) compared to the Australian Healthcare industry average (25.4x).

PE vs Market: HLA is poor value based on its PE Ratio (46.7x) compared to the Australian market (19.8x).


Price to Earnings Growth Ratio

PEG Ratio: HLA is poor value based on its PEG Ratio (1.3x)


Price to Book Ratio

PB vs Industry: HLA is overvalued based on its PB Ratio (3.1x) compared to the AU Healthcare industry average (2.1x).


Future Growth

How is Healthia forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

37.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: HLA's forecast earnings growth (37.3% per year) is above the savings rate (1.9%).

Earnings vs Market: HLA's earnings (37.3% per year) are forecast to grow faster than the Australian market (11.7% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: HLA's revenue (15.6% per year) is forecast to grow faster than the Australian market (5.5% per year).

High Growth Revenue: HLA's revenue (15.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: HLA's Return on Equity is forecast to be low in 3 years time (10.3%).


Past Performance

How has Healthia performed over the past 5 years?

27.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: HLA has a large one-off gain of A$3.4M impacting its June 30 2021 financial results.

Growing Profit Margin: HLA's current net profit margins (3.8%) are higher than last year (3.1%).


Past Earnings Growth Analysis

Earnings Trend: HLA's earnings have grown significantly by 27.8% per year over the past 5 years.

Accelerating Growth: HLA's earnings growth over the past year (91.6%) exceeds its 5-year average (27.8% per year).

Earnings vs Industry: HLA earnings growth over the past year (91.6%) exceeded the Healthcare industry 61.3%.


Return on Equity

High ROE: HLA's Return on Equity (9.9%) is considered low.


Financial Health

How is Healthia's financial position?


Financial Position Analysis

Short Term Liabilities: HLA's short term assets (A$20.8M) do not cover its short term liabilities (A$37.2M).

Long Term Liabilities: HLA's short term assets (A$20.8M) do not cover its long term liabilities (A$85.8M).


Debt to Equity History and Analysis

Debt Level: HLA's debt to equity ratio (54.3%) is considered high.

Reducing Debt: Insufficient data to determine if HLA's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: HLA's debt is well covered by operating cash flow (52.3%).

Interest Coverage: HLA's interest payments on its debt are well covered by EBIT (3.5x coverage).


Balance Sheet


Dividend

What is Healthia current dividend yield, its reliability and sustainability?

2.63%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: HLA's dividend (2.63%) is higher than the bottom 25% of dividend payers in the Australian market (2.27%).

High Dividend: HLA's dividend (2.63%) is low compared to the top 25% of dividend payers in the Australian market (5.32%).


Stability and Growth of Payments

Stable Dividend: Too early to tell whether HLA's dividend payments have been stable as they only just started paying a dividend.

Growing Dividend: Too early to tell if HLA's dividend payments are increasing as they only just started paying a dividend.


Current Payout to Shareholders

Dividend Coverage: With its reasonable payout ratio (69.5%), HLA's dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: HLA's dividends in 3 years are forecast to be well covered by earnings (42.4% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.5yrs

Average management tenure


CEO

Wes Coote

2.5yrs

Tenure

AU$400,402

Compensation

Mr. Wesley James Coote, also known as Wes, B.Com., C.A., ACIS, serves as the Managing Director of Evolve Salons Limited. Mr. Coote has been Group Managing Director, Chief Executive Officer and Director at...


CEO Compensation Analysis

Compensation vs Market: Wes's total compensation ($USD297.19K) is below average for companies of similar size in the Australian market ($USD556.28K).

Compensation vs Earnings: Wes's compensation has increased by more than 20% in the past year.


Leadership Team

Experienced Management: HLA's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.


Board Members

Experienced Board: HLA's board of directors are considered experienced (3.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: HLA insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 96.9%.


Top Shareholders

Company Information

Healthia Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Healthia Limited
  • Ticker: HLA
  • Exchange: ASX
  • Founded: 2018
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: AU$240.590m
  • Shares outstanding: 126.63m
  • Website: https://www.healthia.com.au

Location

  • Healthia Limited
  • East Tower
  • Level 4
  • Bowen Hills
  • Queensland
  • 4006
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/18 15:39
End of Day Share Price2021/10/18 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.